Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Alex Barnes; Dirk Hofmann; Lesley Ann Hall; Sonja Klebe; Réme Mountifield

doi:10.20524/aog.2021.0582

Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Alex Barnes, Dirk Hofmann, Lesley Ann Hall, Sonja Klebe, Réme Mountifield

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.

Original language	English
Pages (from-to)	447-448
Number of pages	2
Journal	Annals of Gastroenterology
Volume	34
Issue number	3
DOIs	https://doi.org/10.20524/aog.2021.0582
Publication status	E-pub ahead of print - 27 Jan 2021

Keywords

Colitis
Esophagitis
Immunotherapy
Inflammatory bowel disease
Ocrelizumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.20524/aog.2021.0582Licence: In Copyright

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079880/Licence: In Copyright

Cite this

@article{a46651a42b8944849d0cec51165af48e,

title = "Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis",

abstract = "Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.",

keywords = "Colitis, Esophagitis, Immunotherapy, Inflammatory bowel disease, Ocrelizumab",

author = "Alex Barnes and Dirk Hofmann and Hall, {Lesley Ann} and Sonja Klebe and R{\'e}me Mountifield",

year = "2021",

month = jan,

day = "27",

doi = "10.20524/aog.2021.0582",

language = "English",

volume = "34",

pages = "447--448",

journal = "Annals of Gastroenterology",

issn = "1108-7471",

publisher = "Hellenic Society of Gastroenterology",

number = "3",

}

TY - JOUR

T1 - Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

AU - Barnes, Alex

AU - Hofmann, Dirk

AU - Hall, Lesley Ann

AU - Klebe, Sonja

AU - Mountifield, Réme

PY - 2021/1/27

Y1 - 2021/1/27

N2 - Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.

AB - Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.

KW - Colitis

KW - Esophagitis

KW - Immunotherapy

KW - Inflammatory bowel disease

KW - Ocrelizumab

UR - http://www.scopus.com/inward/record.url?scp=85106870759&partnerID=8YFLogxK

U2 - 10.20524/aog.2021.0582

DO - 10.20524/aog.2021.0582

M3 - Article

AN - SCOPUS:85106870759

SN - 1108-7471

VL - 34

SP - 447

EP - 448

JO - Annals of Gastroenterology

JF - Annals of Gastroenterology

IS - 3

ER -

Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this